以下の論文は、ガーダシル接種直後に発症した症例ですが、論文中にはガーダシルの記載がありません。
オーストラリアでは、ガーダシルが副反応のないワクチンというコンセンサスができているのか
医師が発表する論文にさせ記載できない状況です。
この後、イギリス、アメリカでもガーダシル後の発症が報告されています。
中年の男女に好発する疾患として知られていた疾患です。

胃腸運動障害(胃麻痺、便秘)、膀胱機能障害、ドライアイ、ドライマウス、起立性低血圧
運動・感覚障害
治療は、IVIg、血漿交換、リツキシマブ

http://blog.goo.ne.jp/hazukimutsukinagatsuki/e/54f8e48b0047bd62e5f07f8324612579
http://blog.goo.ne.jp/hazukimutsukinagatsuki/e/557e8f636a7ba2e10f289bd856182d0c
http://blog.goo.ne.jp/hazukimutsukinagatsuki/e/f664bba4f16c7a87d133d9b31b726a23
http://blog.goo.ne.jp/hazukimutsukinagatsuki/e/c8a8e269143ee652c2da164254ca1700
http://blog.goo.ne.jp/hazukimutsukinagatsuki/e/e1bfc6a82d1c05a3d479dd29594f38ea
日本のサーバリックス接種後にも、二人の少女に抗ガングリオニックAChR抗体α3が検出されている
Patients
A total of 15 000 patients seen at Mayo Clinic (2005–2007) and evaluated on a service basis for paraneoplastic neurological autoimmunity for whom clinical information was obtained retrospectively by medical record review as well as 457 neurologically asymptomatic patients or control subjects of whom 173 were healthy, 245 had lung cancer, and 39 had systemic lupus erythematosus or Sjögren syndrome.
Outcome Measures
Neurological, oncological, and serological associations of α3-AChR autoantibody seropositivity.
Results
Of 15 000 patients tested on a service basis, 1% were seropositive (median, 0.12 nmol/L; range, 0.03–18.8 nmol/L; normal, ≤0.02 nmol/L), 55% were male, and the median age was 65 years. Cancer was found (new or by history) in 24 of 78 patients evaluated for cancer while at Mayo Clinic (30%); 43% had adenocarcinoma (more patients had breast cancer than prostate, lung, and gastrointestinal cancers; each of the latter groups had about the same number of patients). Of 12 patients with high antibody values (≥1.00 nmol/L), 83% had pandysautonomia. Of 85 patients with medium antibody values (0.10–0.99 nmol/L), neurological presentations were more diverse and included peripheral neuropathies (36%), dysautonomia (20%, usually limited), and encephalopathy (13%). Of 58 patients with low antibody values (0.03–0.09 nmol/L), 54% had a nonautoimmune neurological disorder or no neurological disorder. Of 245 control patients with lung cancer, 7.8% were seropositive. Only 1 of 212 control patients without cancer (0.5%) was seropositive (P<.001).
Conclusion
The detection of α3-AChR autoantibody aids the diagnosis of neurological autoimmunity and cancer.